Health
The 15-20 National Hospital and GenSight Biologics Announce the Treatment of the First Patient in the GS010/LUMEVOQ® REVISE Study
PARIS, February 10, 2026--Regulatory News: The 15-20 National Hospital (l’Hôpital national des 15-20) in Paris and GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the treatment of the first patient enrolled in the REVISE dose-ranging study. The open-label, single center study aims to enroll
About this update from Gensight Biologics Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/f29b308bed9aa1bf395a690eb43b8804"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QV1bZ8uVlngGYijATXGehw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f29b308bed9aa1bf395a690eb43b8804","width":480,"height":204}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First of 14 planned patients for the dose-ranging study approved by the ANSM in December 2025","length":93,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Clinical study marks continuing partnership between the 15-20 Hospital and GenSight Biologics to develop transformative treatments for rare diseases","length":148,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":241,"olType":false},{"type":"text","content":"PARIS, February 10, 2026--(BUSINESS WIRE)--Regulatory News:","length":59,"tagName":"p"},{"type":"text","content":"The 15-20 National Hospital (l’Hôpital national des 15-20) in Paris and GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the treatment of the first patient enrolled in the REVISE dose-ranging study. The open-label, single center study aims to enroll 14 patients in France.","length":480,"tagName":"p"},{"type":"text","content":"With REVISE now underway, the hospital is currently the only institution in Europe with a clinical study involving GS010/LUMEVOQ®, GenSight Biologics’ candidate gene therapy being developed as a treatment for Leber Hereditary Optic Neuropathy (LHON) caused by a mutated ND4 mitochondrial gene1. The hospital is also the sole institution in Europe authorized to perform named patient early access (AAC) treatments with GS010.","length":424,"tagName":"p"},{"type":"text","content":""As a leading hospital specialized in the treatment of vision disorders, 15-20 National Hospital is committed to supporting the most promising scientific advances rigorously and in the service of patients affected by rare diseases," said...